
OKUR Stock Forecast & Price Target
OKUR Analyst Ratings
Bulls say
OnKure Therapeutics is well positioned by a differentiated structure-based platform that is advancing OKI-345 and OKI-355 as selective inhibitors of mutant PI3Kα while sparing wild-type PI3Kα, a design that could improve efficacy and tolerability versus older targeted agents. The company’s recent quarterly update and KOL event reinforced the scientific rationale for broader hotspot coverage, deeper target inhibition, and a wider therapeutic index, while preclinical data showed strong cellular selectivity across PI3KαH1047R, PI3KαE545K, and PI3KαE542K. Financially, OnKure ended 2Q with $176M in cash, which should fund operations into 2029, supporting continued development through anticipated IND submissions in 1H27 and expanding its clinical and commercial opportunity in PI3Kα-driven cancers.
Bears say
OnKure Therapeutics is a clinical-stage biopharmaceutical company with no operating revenue shown in the provided data, and the “Collaboration revenue, related party” line reported as a dash underscores the lack of meaningful commercial traction. Its business remains concentrated in a single clinical research segment and heavily dependent on unproven precision-medicine programs, especially the PI3Kα-focused OKI-219, which increases binary clinical and development risk. With no evidence here of diversified revenue streams, approved products, or scale, the fundamental story appears reliant on future trial success rather than current financial performance.
This aggregate rating is based on analysts' research of OnKure Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
OKUR Analyst Forecast & Price Prediction
Start investing in OKUR
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About OnKure Therapeutics Inc (OKUR) Forecast
OKUR Analyst Forecast & Price Prediction
Start investing in OKUR
Order type
Buy in
Order amount
Est. shares
0 shares